Genezen – a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO) – recently announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners. The funding will accelerate Genezen’s growth trajectory in retroviral, lentiviral, and adeno-associated viral (AAV) vector manufacturing and support the execution of a robust pipeline of customer projects for innovators developing groundbreaking cell and gene therapies.
Genezen operates as a contract development and manufacturing organization (CDMO) with a decade’s experience at the heart of the rapid growth in the gene and cell therapy market. And Genezen is a leader in the supply of retroviral vectors, lentiviral vectors, and AAV. Led by an extremely experienced team, a science-first approach influences continual investment in scalable, high-yield manufacturing processes and best-in-class technologies.
Genezen recently completed the qualification of its 25,000 sq ft GMP viral vector facility in Fishers, Indiana.
KEY QUOTES;
“This is an exciting development for Genezen, continuing its momentum towards becoming a premier CDMO for cell and gene therapy innovators. A decade of experience in advanced therapies has helped us identify the need for a versatile, scientifically rigorous, and technically focused CDMO partner like Genezen. With Ampersand’s strong partnership and support, Genezen will continue to deliver best-in-class development and manufacturing solutions for cell and gene therapies, accelerating the delivery of life-saving treatments to patients across the globe.”
“We are pleased to see that our LVV and AAV capabilities have generated so much attention in the market. This capital infusion will enable us to accelerate our growth and expansion plans at our Fishers site, including further technology investments, and build-out of additional state-of-the-art laboratories, manufacturing suites, and support areas, which will complement our current capacity and allow us to support additional cell and gene therapy innovators.”
— Steven Favaloro, President and CEO of Genezen
“Given the ongoing rapid growth of the cell and gene therapy sector, we are excited to continue our support of Genezen. With its state-of-the-art GMP facility, the entire Genezen team has demonstrated a unique ability to develop robust capabilities that resonate with the market. Clients are drawn to the team’s scientific expertise, and this equity financing will enable continued development and growth for Genezen.”
— David Anderson, General Partner at Ampersand Capital Partners
